Back
Renal failure has been a concern for several decades. Chronic kidney Disease (CKD) is a progressive condition that affects more than the 10% of the population around the world, been more prevalent in older people, women and people with comorbidities such as hypertension and diabetes type 2. Nowadays the mainly CKD’s treatment are hemodialysis (HD) and kidney transplantation. HD is, relatively, an inconvenient treatment due to its consuming process, affecting the quality of life of the patient. In order to solve this problem, new alternatives have been proposed. Hemoperfusion (HP) is the best technique to remove uremic toxins by adsorption, also it has shown a great potential in the blood purification aspect. In this study we report highlights of the use of HP using JAFRON HA130 cartridges in the Mexican population cohorts in the context of multiple chronic inflammatory conditions in order to support evidence of the effectiveness and safety available in the literature.
In this study we aim to investigate the efficacy and safety of a new hemoperfusion (HP) cartridge (JAFRON HA130) combined with standard therapy (fluid resuscitation, vasopressors, anticoagulants and antimicrobial treatment) in chronic hemodialysis patients with persistent uremic symptoms. We retrospectively analyzed the medical records of 22 adult patients (72% males, mean age 58.2 years old) with advanced Chronic Kidney Disease (≥3) receiving any form of dialysis with persistent uremic symptoms such as pruritus, astenia, dizziness, sleep disturbances, peripheral neuropathy and hyperphosphatemia. All of the patients received 2 sessions of HDF + HA130 cartridge, 4 hrs per session, two weeks between sessions. Blood sampling was carried out before and after the procedures, the parameters we determined were: creatine in blood, blood urea nitrogen, urea, phosphate (P) and parathyroid hormone. At the same time the pittsburgh sleep quality index, restless leg syndrome scale, DUO’s pruritus score and visual analog scale were evaluated
Conclusions
The development in new cartridges technology allows more wide applications for renal patients. As we expand to involve other indications for this therapy there is cost-effectiveness improvement for the patients. More studies in different clinical settings are needed in order to achieve adsorption therapy national recommendations.